Drive payer submission readiness for Phase 2 and 3 product

The license agreement will feature an upcoming Phase III trial and—depending on results—the development, manufacturing, and commercialization of evenamide as a potential treatment option.

Nicholas Saraceno offers an overview of the legislation and how it impacts the pharma supply chain.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

Rob Sobie outlines the importance of supply chain transparency for the benefit of patients.

How will supply chains in the space continue to develop?

As a result, the provider increases its involvement in the country’s pharma sector.